#47 Clinical Context
Background information relevant to the evolving cannabis medicine landscape.
Clinicians should counsel patients with GERD or at risk for reflux disease that cannabis use may exacerbate symptoms through relaxation of the lower esophageal sphincter, potentially worsening disease progression and treatment outcomes. This finding is particularly relevant for patients considering cannabis for symptom management of other conditions, as the gastrointestinal risks may outweigh perceived benefits and complicate existing GERD treatment plans.
A recent study has identified an association between cannabis use and increased risk of gastroesophageal reflux disease (GERD), particularly in patients with concurrent substance use disorders. The research suggests that cannabis may compromise lower esophageal sphincter function or alter gastric motility through cannabinoid effects on the enteric nervous system, leading to increased acid reflux symptoms. These findings are relevant to clinicians prescribing cannabis for chronic conditions, as GERD represents both a common comorbidity and a potential adverse effect that should be monitored during treatment. Patients with preexisting reflux disease or those prone to substance use disorders may warrant careful risk-benefit assessment before initiating cannabis therapy. Clinicians should counsel patients about potential gastrointestinal symptoms and consider alternative therapeutic options or gastroprotective measures in susceptible populations.
“What we’re seeing in observational data is an association between cannabis use and GERD symptoms, but I want to be clear that correlation doesn’t establish causation here, and we haven’t yet isolated whether it’s the cannabis itself, frequency of use, method of consumption, or confounding lifestyle factors driving this relationship. Until we have controlled trials specifically examining cannabis and GERD mechanisms, I’m counseling patients with reflux disease to be cautious and monitor their symptoms if they use cannabis, rather than making definitive recommendations either way.”
💊 While this study highlights an association between cannabis use and gastroesophageal reflux disease, clinicians should recognize that the reported link may reflect confounding factors including concurrent smoking, alcohol use, or underlying gastrointestinal conditions rather than a direct pharmacologic effect of cannabis alone. The mechanism by which cannabis might increase GERD risk remains unclear, as cannabinoids have complex and sometimes contradictory effects on lower esophageal sphincter pressure depending on route of administration and individual metabolism. Patients with existing GERD who use cannabis should be counseled that smoking or vaping cannabis, like tobacco smoke, may relax the lower esophageal sphincter and worsen symptoms, whereas the effects of edibles are less well characterized. Given the prevalence of cannabis use in many populations, asking patients about their consumption patterns during GERD assessment may help identify a modifiable risk factor worth addressing alongside standard lifestyle and dietary interventions. Until
This topic comes up in consultations often.
Dr. Caplan offers clinical context on evolving cannabis policy and its real-world implications for patients.
Book a consultation →💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
